KRAS and colorectal carcinoma: Although the international field has made great progress in drug‐targeted therapy and immunotherapy for CRC in recent years, the genetic status of KRAS, NRAS, BRAF, MSI/MMR, PIK3CA/PIK3CB, etc. in patients with CRC suggests that less than one‐third of patients can successfully benefit from drug‐targeted therapy and immunotherapy, and less than 8% of patients can benefit from PD‐1 [83, 84].